These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27390032)

  • 21. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
    Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
    Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
    Heise T; Piras de Oliveira C; Juneja R; Ribeiro A; Chigutsa F; Blevins T
    Diabetes Obes Metab; 2022 Sep; 24(9):1689-1701. PubMed ID: 35593434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New developments in the treatment and monitoring of type 1 diabetes mellitus].
    Otto-Buczkowska E; Jarosz-Chobot P; Tucholski K
    Endokrynol Pol; 2008; 59(3):246-53. PubMed ID: 18615401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin analogues for type 1 diabetes in children and adolescents.
    Galli-Tsinopoulou A; Stergidou D
    Drugs Today (Barc); 2012 Dec; 48(12):795-809. PubMed ID: 23243636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials.
    Kapur R; Mittra S; Tonpe G; P A; Raj P; Gudat U; Athalye SN
    Expert Opin Biol Ther; 2024 Jun; 24(6):543-561. PubMed ID: 38934226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes.
    Philotheou A; Arslanian S; Blatniczky L; Peterkova V; Souhami E; Danne T
    Diabetes Technol Ther; 2011 Mar; 13(3):327-34. PubMed ID: 21291333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin analogs in the treatment of type II diabetes and future perspectives.
    Sebastian SA; Co EL; Mehendale M; Hameed M
    Dis Mon; 2023 Mar; 69(3):101417. PubMed ID: 35487767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart.
    Thrasher J; Bhargava A; Rees TM; Wang T; Guzman CB; Glass LC
    Endocr Pract; 2015 Mar; 21(3):247-57. PubMed ID: 25370322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G; Del Prato S; Arcari R; Bellomo Damato A; Benzi L; Bruttomesso D; Calderini MC; Coscelli C; Fedele D; Galluzzo A; Giordano M; Giorgino R; Lapolla A; Orsini P; Pagano G; Santoro D; Riccardi G
    Nutr Metab Cardiovasc Dis; 2001 Jun; 11(3):168-75. PubMed ID: 11590992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
    Home PD
    Diabetes Obes Metab; 2012 Sep; 14(9):780-8. PubMed ID: 22321739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.
    Owens DR; Bolli GB
    Diabetes Obes Metab; 2020 May; 22(5):743-754. PubMed ID: 31930670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
    Lindholm A; Jacobsen LV
    Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes. Pharmacoeconomic analysis of cost-effectiveness].
    Costa Pinel B; Belmonte Serrano M; Páez Vives F; Sabaté Obiol A; Estopá Sánchez A; Borrás Borrás J
    Rev Clin Esp; 2001 Aug; 201(8):448-54. PubMed ID: 11599156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addressing hyperglycemia from hospital admission to discharge.
    Moghissi ES
    Curr Med Res Opin; 2010 Mar; 26(3):589-98. PubMed ID: 20078323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
    Ulrich H; Snyder B; Garg SK
    Vasc Health Risk Manag; 2007; 3(3):245-54. PubMed ID: 17703632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Insulin Lispro (Lys B28, Pro B29) treatment in adolescents and young people with type 1 diabetes].
    Tuset Castellano MJ; Martínez Badás I; Alonso Blanco M; Barrio Castellanos R
    An Esp Pediatr; 2000 Apr; 52(4):334-8. PubMed ID: 11003924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.